Zearalenone induces apoptosis and inhibits proliferation in porcine ileal Peyer's patch lymphocytes.

Zearalenone (ZEN) is one of the most active natural estrogenic compounds that induces apoptosis. This study has been prompted by the widespread occurrence of ZEN in food and feed and limited knowledge about the effects of exposure to low doses of ZEN on the immune system. The aim of the study was to verify the hypothesis that low doses of ZEN contribute to induction of apoptosis and inhibition of proliferation in lymphocytes of the germinal centers (GC) of ileal Peyer's patches (IPP) in pigs. The experiment was performed on 30 female Polish Large White pigs, aged 2 months, with body weight of 15-18 kg, divided into two groups: control (C, n = 15) and experimental (Z, n = 15). On days 14, 28 and 42 of exposure to ZEN (100 µg kg(-1) feed day(-1)), apoptosis in IPP GC was evaluated histologically in HE-stained specimens, immunohistochemically by active caspase-3 staining and in mononucleosome and oligonucleosome detection-based ELISA. Proliferation was evaluated histologically by mitosis detection in HE-stained specimens, immunohistochemically by PCNA staining and in the MTT tetrazolium salt colorimetric assay detecting mitogenic responses of B cells to LPS. Exposure to low doses of ZEN for several weeks intensified apoptosis and weakened proliferation in IPP lymphocytes. ZEN influences gut-associated lymphoid tissue (GALT) by decreasing the expression of CD21+ on B cells and by increasing the percentage of B1 cell populations.

Distribution of lymphomas in Poland according to World Health Organization classification: analysis of 11718 cases from National Histopathological Lymphoma Register project - the Polish Lymphoma Research Group study.

Most national lymphoma registers rely on broad classifications which include Hodgkin and non-Hodgkin lymphomas (NHL), multiple myeloma and leukaemia. In Poland the National Histopathological Lymphoma Register project (NHLR) was implemented by hematopathologists in accordance with the 2008 WHO classification into haematopoietic and lymphoid tissues. We present the NHLR data and compare lymphoma distribution in Poland, Europe, as well as in North Central and South America. Records of 11718 patients diagnosed in 24 pathology departments from all over the country were retrieved and reclassified into indolent and aggressive lymphomas according to the 2008 revised WHO classification system. DLBCL (32.9%; 2587), CLL/SLL (31.84%; 2504) and MCL (9.04%; 711) were the three most frequent NHL. The ratio of indolent to aggressive NHL was 1.72; 63.25% (4809) to 36.25% (2794) of cases respectively. Multiple myeloma was less frequent as compared to the data from population-based national cancer register (13.32% vs. 28.94%). Major differences between NHLR and European and American data on NHL subtypes concered: higher incidence of aggressive B-cell lymphomas including DLBCL, lower FL and MALT incidence rate. The percentage of unclassified lymphomas in the study was minimal due to participation of hematopathologists.